AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)

AlloNK (GCC4001) - Artiva Biotherapeutics

Rituxan (rituximab) - Roche

AFM13/AB-101 - Affimed, GC Biopharma

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

Adcetris (brentuximab vedotin) - Takeda, Pfizer

acimtamig (AFM13) - Affimed

https://ash.confex.com/ash/2023/webprogram/Paper174250.html

Alison Moskowitz, MD1; Andreas Harstrick2; Michael Emig, MD2; Andre Overesch2; Sheena Pinto2; Paulien Ravenstijn2; Thomas Schlüter2; Jennifer Rubel3; Hans Rebscher2; Thorsten Graefe4; John Lim4; Heather Raymon4; Karenza Alexis3

Nov 3, 2023